Coagulants
-
Subject Areas on Research
- A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial.
- Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8.
- Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management.
- Critical role for mouse marginal zone B cells in PF4/heparin antibody production.
- Cryoprecipitate therapy.
- Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.
- Domino liver transplantation in maple syrup urine disease: a case report and review of the literature.
- Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial.
- Effects of a plasma-derived C1 esterase inhibitor on hemostatic activation, clot formation, and thrombin generation.
- Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial.
- Factor concentrates for perioperative bleeding: old drugs with new approaches.
- Heparin-induced decrease in circulating antithrombin-III.
- In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition.
- Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons.
- Obstetric hemorrhage.
- Procoagulant effects of intraocular sodium hyaluronate (Healon) after phakic diabetic vitrectomy. A prospective, randomized study.
- Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?
- Safe application of a restrictive transfusion protocol in moderate-risk patients undergoing cardiac operations.
- The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
- When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.